| Oct 30 |
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years
|
| Oct 10 |
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Oct 3 |
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
|
| Aug 27 |
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
|
| Aug 10 |
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 8 |
SCYNEXIS GAAP EPS of -$0.30 misses by $0.10
|
| Aug 8 |
Scynexis: Q2 Earnings Snapshot
|
| Aug 8 |
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 23 |
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
|
| May 31 |
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
|
